Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 14,147 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Insomnia, Depressive Disorder, Major
Interventions: Eszopiclone, Placebo; Drug · Other
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 65
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 62 more

Conditions: Rheumatoid Arthritis
Interventions: Methoxsalen, Extracorporeal Photopheresis; Drug · Procedure
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 10
States / cities: Westminister, Maryland • Worchester, Massachusetts • Morristown, New Jersey + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 36
States / cities: Long Beach, California • Pasadena, California • Denver, Colorado + 32 more

Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions: Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Montclair, California • Hialeah, Florida • Miami Lakes, Florida + 5 more

Conditions: Acne Vulgaris
Interventions: BPX-01 1% Minocycline Topical Gel, BPX-01 2% Minocycline Topical Gel, BPX-01 Vehicle Topical Gel; Drug
Lead sponsor: BioPharmX, Inc.; Industry
Eligibility: 9 Years to 40 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Santa Monica, California • Coral Gables, Florida • Lake Mary, Florida + 12 more

Conditions: Rheumatoid Arthritis
Interventions: CFZ533, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Anniston, Alabama • Miami, Florida • South Miami, Florida + 2 more

Conditions: Healthy Volunteers
Interventions: VEL-101, Placebo; Drug
Lead sponsor: Asahi Kasei Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Compare Ecchymosis and Edema for Fibrin Sealant and no Fibrin Sealant
Interventions: Fibrin Sealant (Artiss); Drug
Lead sponsor: Nguyen, Davis B., M.D.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Idiopathic Hypersomnia
Interventions: JZP-258, Placebo Oral Solution; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 40
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more

Conditions: Asthma, Status Asthmaticus
Interventions: Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Sylmar, California + 6 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Interferon-gamma 1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: 20 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hemorrhoids
Interventions: Bupivacaine HCl, SKY0402; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Birmingham, Alabama • Montgomery, Alabama • Pasadena, California + 16 more

Conditions: PTSD, Suicidal Ideation, Suicide, Attempted, Trauma, Psychological
Interventions: Prolonged exposure; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Volunteers
Interventions: BGB-23339, Placebo; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Tobacco Smoking
Interventions: Genetic Education Session, Nutrition Education Session; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hip Fracture
Interventions: PLX-PAD, Placebo; Drug
Lead sponsor: Pluristem Ltd.; Industry
Eligibility: 0 Years to 90 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Sacramento, California • Denver, Colorado • Indiana, Pennsylvania

Conditions: Contraceptive Devices, Long-Acting Reversible Contraception, Analgesia, Adolescent Health, Gynecology
Interventions: Nitrous oxide gas for inhalation, Oxygen Gas for Inhalation; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 14 Years to 24 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19
Interventions: Ampion, Standard of Care; Biological · Other
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Overweight or Obesity
Interventions: Olatorepatide, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Mobile, Alabama • Walnut Creek, California • Waterbury, Connecticut + 17 more

Conditions: Spinal Cord Injuries and Disorders (SCI/D)
Interventions: Caring Connections, Attention control; Other
Lead sponsor: Chicago Association for Research and Education in Science; Other
Eligibility: 18 Years to 90 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more

Conditions: Type 2 Diabetes
Interventions: Colesevelam hydrochloride; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 45
States / cities: Tuscumbia, Alabama • Sierra Vista, Arizona • Jonesboro, Arkansas + 42 more

Conditions: Anxiety Disorders
Interventions: AZD7325, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 52
States / cities: Birmingham, Alabama • Tucson, Arizona • Arcadia, California + 49 more

Conditions: Rheumatoid Arthritis
Interventions: AMG 357, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 25 Years to 70 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Duncansville, Pennsylvania • Dallas, Texas

Search by objective public record fields.

A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis

A New Oral Treatment For Type II Diabetes Mellitus

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Efficacy and Safety of Fibrin Sealant (FS) VH S/D-APR for Hemostasis and Wound Healing in Endoscopic Browlift

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

Enhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

Developing Genetic Education for Smoking Cessation

Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)

Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women

Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Caring Connections: A Program to Alleviate Social Isolation and Loneliness in Individuals Living With Spinal Cord Injury

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

WelChol® and Insulin in Treating Patients With Type 2 Diabetes

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis